Joseph P. Hagan - May 10, 2022 Form 4 Insider Report for Regulus Therapeutics Inc. (RGLS)

Role
President and CEO, Director
Signature
Christopher Aker, Attorney in Fact
Stock symbol
RGLS
Transactions as of
May 10, 2022
Transactions value $
$0
Form type
4
Date filed
5/11/2022, 04:54 PM
Previous filing
Jan 26, 2022
Next filing
May 20, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RGLS Stock Option (Right to Buy) Award $0 +300K $0.00 300K May 10, 2022 Common Stock 300K $1.31 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests only upon achievement of a performance-based milestone. The performance criteria were met, resulting in vesting of the option. Upon achievement of the milestone and verification of same by the Company's Compensation Committee, one hundred percent of the shares immediately vested.